CONCLUSION

In conclusion, advancements in genetic research and novel technologies, such as NGS, scRNA-seq, and liquid biopsies, are enhancing our understanding of iCCA. These advancements provide an enhanced understanding of tumor heterogeneity, clonal evolution, and resistance mechanisms, facilitating the formulation of more precise and effective treatment strategies. Genetic profiling has transformed personalized medicine by enabling clinicians to customize therapies according to specific genomic mutations, including FGFR2 fusions, IDH1/IDH2 mutations, and BAP1 alterations. Targeted therapies based on genomic insights enhance treatment efficacy and reduce toxicity, thereby improving patient quality of life. In addition to optimizing treatment, genetic-based preventive strategies offer significant potential for risk stratification and early intervention. Identifying individuals with genetic markers or familial risk factors enables clinicians to implement proactive surveillance strategies, potentially facilitating earlier detection and enhancing prognosis. Integrative multi-omics approaches are revealing new biomarkers that could function as potential therapeutic targets, facilitating advancements in precision oncology. Immunotherapy is increasingly prominent in iCCA research, with checkpoint inhibitors and combination strategies demonstrating potential, especially in tumors exhibiting microsatellite instability (MSI) or mismatch repair deficiency (dMMR). These advancements indicate a transition to a more personalized approach, wherein treatment decisions are informed by a thorough molecular analysis of each patient's tumor profile. Ongoing research necessitates collaborative international efforts and extensive genomic studies to enhance therapeutic interventions and optimize patient outcomes. The future of iCCA treatment is progressing towards a precision-based approach, incorporating molecular diagnostics, targeted therapies, and immunomodulation, with the goal of improving survival rates and overall quality of life for affected individuals.